Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.55 |
| ▸ | MGAM | O43451 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | SI | P14410 | 3/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692348 | 0.88 | LTA4H (0.59) | LTA4HNR5A1DRD4DRD2DRD3 | |
| SCHEMBL8140756 | 0.87 | NPC1 (0.47) | LTA4HMGAMGAASIMGAM2 | |
| SCHEMBL21538787 | 0.87 | MAPT (0.54) | LTA4HNR5A1MGAMGAASI | |
| SCHEMBL9451166 | 0.87 | LMNA (0.54) | GAALMNAESR1ESR2 | |
| SCHEMBL15227716 | 0.86 | NR5A1 (0.62) | LTA4HNR5A1DRD4DRD2DRD3 | |
| SCHEMBL226548 | 0.85 | LTA4H (0.64) | LTA4HNR5A1DRD4DRD2DRD3 | |
| SCHEMBL10921904 | 0.85 | NR5A1 (0.66) | LTA4HNR5A1GAADRD4DRD2 | |
| SCHEMBL3227718 | 0.85 | NR5A1 (0.66) | LTA4HNR5A1GAADRD4DRD2 | |
| SCHEMBL13749668 | 0.85 | NR5A1 (0.66) | LTA4HNR5A1GAADRD4DRD2 | |
| SCHEMBL2470706 | 0.82 | NR5A1 (0.75) | LTA4HNR5A1DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109461-A1 | BENZOTHIOPHENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-22 | — | — | WO | disclosed |
| CN-116265458-A | Benzothiophene derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| EP-2819993-B1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | UNIV CINCINNATI (US) | 2020-09-02 | — | — | EP | disclosed |
| US-9394233-B2 | ROS-activated compounds as selective anti-cancer therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2819993-A1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | University Of Cincinnati (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2268646-B9 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2268646-B1 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013130968-A1 | ROS-ACTIVATED COMPOUNDS AS SELECTIVE ANTI-CANCER THERAPEUTICS | UNIVERSITY OF CINCINNATI (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2013-09-05 | — | — | US | disclosed |
| US-8357684-B2 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-22 | — | — | US | disclosed |
| US-4329289-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4314085-A | Intermediates for preparing adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4310527-A | DISORDERS OF CAROIAC RHYTHM AND CORONARY HEART DISEASES AND HYDPERTENSION | CIBA-GEIGY CORPORATION (US) | 1982-01-12 | — | — | US | disclosed |
| US-4304721-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-12-08 | — | — | US | disclosed |
| US-4301300-A | ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-11-17 | — | — | US | disclosed |
| US-4285873-A | ANTIANDROGENS | HOFFMANN-LA ROCHE INC. (US) | 1981-08-25 | — | — | US | disclosed |
| US-4281189-A | Sulfonamide intermediates for adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4278608-A | Adrenergic blocking agents | HOFFMANN-LA ROCHE INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4247710-A | THE 3'-HYDROXY, -BENZYLOXY, OR -HALO DERIVATIVES OF METHYL 4-((2'-HYDROXYPROPYL)OXY)PHENYLACETATE | HOFFMANN-LA ROCHE INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4202978-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE, ANTISECRETORY, SPASMOLYTIC | HOFFMANN-LA ROCHE INC. (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230542-A1 | ROS-Activated Compounds as Selective Anti-Cancer Therapeutics | ROS1, NOX4, NOX1 | LTA4H 3566/4885NR5A1 4292/4885MGAM 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.